Pricing Log in Create free account
Friday 6 November 2026 Export XERS’s income statement to Excel — free account

Xeris Biopharma Holdings, Inc.

XERS Healthcare Drug Manufacturers Specialty & Generic

Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.

Revenue
+44.2%
EPS
+1,479.0%
Free cash flow
+93.2%
Total debt
−13.6%

Quarter to September 2026, against a year earlier

15.16 2.08 +15.90%
Market cap
$2.4B
P/E
0.0×
Fwd P/E
−143×
Dividend yield
—
F-score
8/9
Altman Z
0.98
Beneish M
−2.58
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Xeris Biopharma Holdings, Inc. (XERS) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, Xeris Biopharma Holdings, Inc. (XERS) trades at a EV/Sales of 7.8×. Over the past ten years it has ranged from −23.1× (September 2018) to 228× (November 2018); the current reading is higher than 71% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.8× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 4.7× 45.98%
FY2024 3.2× 22.57%
FY2023 2.6× 33.35%
FY2022 2.0× (55.35%)
FY2021 4.4× (45.35%)
FY2020 8.1× (86.98%)
FY2019 62.4× 21.88%
FY2018 51.2× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 5.0× 12.50%
Jun 2026 4.5× 26.77%
Mar 2026 3.5× (25.44%)
Dec 2025 4.7× (14.47%)
33 more quarters

Against its own ten years

Low −23.1× High 228×
Ten-year median 4.2×
Current reading's percentile 70

EV/Sales against peers

Company EV/Sales
HCM HUTCHMED (China) Limited Sponsored ADR compare −0.1×
RGC Regencell Bioscience Holdings Limited compare n/m
PRGO Perrigo Company plc compare 1.2×
TRLV Trulieve Cannabis Corp. compare 2.1×
BCRX BioCryst Pharmaceuticals, Inc. compare 2.5×
PBH Prestige Consumer Healthcare Inc. compare 3.5×
XERS Xeris Biopharma Holdings, Inc. 7.8×
ALVO Alvotech compare 8.8×
AMLX Amylyx Pharmaceuticals, Inc. compare 34.4×
Drug Manufacturers Specialty & Generic industry median 2.8×
Healthcare sector median 3.6×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on XERS